Friday, February 13, 2015
Raptor Pharma: Finding a Cure for Debilitating Diseases
Nephropathic cystinosis is a disorder that starts during infancy and would later on blossom to create complications in the kidneys. This disease is considered as one of the debilitating diseases that could be fatal if left untreated.
Raptor Pharmaceuticals Corp is a biopharmaceutical company that focuses its resources in the development of drugs that are intended to treat life-altering diseases like nephropathic cystinosis. In the United States, their PROCYSBI has already been given approval to be marketed for adults and children 6 years old and above. This product is also marketed in 28 other countries that are members of the European Commission. The company continues to research and develop products that would cure diseases like Huntington’s diseases, mitochondrial disorders and non-fatty liver diseases.
Founded in 2005, the company holds its corporate office in Novato, California. Its strategic partnerships with other companies allow Raptor Pharmaceutical to further advance and hasten the development of their product candidates.